Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05927532 · ClinicalTrials.gov registry record · NA
Argyle Safety Fistula Cannula With Anti-reflux Valve Clinical Study
A NA study of End Stage Renal Failure on Dialysis, sponsored by Mozarc Medical US.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT05927532: Completed NA study of End Stage Renal Failure on Dialysis, sponsored by Mozarc Medical US.
NCT05927532 is a NA study of End Stage Renal Failure on Dialysis that has completed, run by Mozarc Medical US. The registered enrollment target is 40 participants, below the 270-participant average among 3 other End Stage Renal Failure on Dialysis trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05927532, a NA study of End Stage Renal Failure on Dialysis, has completed, sponsored by Mozarc Medical US.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the investigation is to confirm the safety and performance of the Argyle™ Safety Fistula Cannula with Anti-reflux Valve for hemodialysis treatment.
Primary Outcome
The primary objective is the percentage of successful hemodialysis sessions using the Argyle™ Safety Fistula Cannula with Anti-reflux Valve.
Conditions Studied
Interventions
- DEVICE Argyle Safety Fistula Cannula with Anti-Reflux Valve
Study Locations (3)
Connecticut
- DaVita Hartford - Hartford
Georgia
- DaVita Columbus - Columbus
Virginia
- DaVita Norfolk - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-03-10 |
| Est. Completion | 2024-12-15 |
| Phase | NA |
What the finished NCT05927532 record still lists
NCT05927532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 270-participant average among 3 other End Stage Renal Failure on Dialysis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with End Stage Renal Failure on Dialysis appearing as the primary indexed condition, and to 1 intervention - of which Argyle Safety Fistula Cannula with Anti-Reflux Valve is the first listed.
NCT05927532 reports a single indexed study location in Connecticut, Georgia, Virginia.
Frequently Asked Questions
What is clinical trial NCT05927532 about?
NCT05927532 is a clinical study titled "Argyle Safety Fistula Cannula With Anti-reflux Valve Clinical Study". The purpose of the investigation is to confirm the safety and performance of the Argyle™ Safety Fistula Cannula with Anti-reflux Valve for hemodialysis treatment.
What is the current status of trial NCT05927532?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2024-03-10. Estimated completion is 2024-12-15.
What conditions does trial NCT05927532 study?
This clinical trial studies the following conditions: End Stage Renal Failure on Dialysis.
What interventions are being tested in trial NCT05927532?
The interventions under investigation include: Argyle Safety Fistula Cannula with Anti-Reflux Valve (DEVICE).
Who is sponsoring clinical trial NCT05927532?
This trial is sponsored by Mozarc Medical US, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05927532 being conducted?
This trial has 3 study locations across Connecticut, Georgia, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Failure on Dialysis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI